A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
65
Years old
Gender
All
Therapeutic area :
Oncology
Disease :
Leukaemia
Study medication :
F60002
Phase :
Phase II
Start Date :
May 17, 2010
End date :
June 19, 2014
Study ID :
F60002 IN 202 G0
EudraCT/CTIS number :
2009-016601-42
Send by email